Paregoric Kid
02-22-2007, 10:08 AM
Adolor is also working on several delta agonists to be used as analgesics. the main candidate is called ADL5859.
Delta Agonist Program
Through a proprietary research platform based on cloned, human opioid receptors, we have identified a series of novel, orally active Delta agonists that selectively stimulate the Delta opioid receptor. Adolor’s lead Delta candidate, ADL5859, has demonstrated activity in several preclinical studies and is currently in Phase 1 clinical development. A second compound, ADL5747, is targeted for an investigational new drug application (IND) by year end 2007. On the basis of preclinical evaluation in animal models of human conditions, one might expect a Delta agonist to show effect in inflammatory pain, among other pain conditions. In addition, Delta agonists are thought to modulate other biological processes that may manifest themselves in disease states or conditions such as overactive bladder and depression.
With no selective Delta agonists currently approved by the FDA, our Delta program is expanding the frontiers of pain research.
interestingly they are also working on a way to deliver this drug to inflammed parts of the body as there is proof that opioids applied directly to inflamed tissue like skin, eyes, and joints also reduces pain transmission. this is called peripheral opioid analgesia. they are trying to selectively stimulate opioid receptors in inflammed tissue and not in the CNS.
Delta Agonist Program
Through a proprietary research platform based on cloned, human opioid receptors, we have identified a series of novel, orally active Delta agonists that selectively stimulate the Delta opioid receptor. Adolor’s lead Delta candidate, ADL5859, has demonstrated activity in several preclinical studies and is currently in Phase 1 clinical development. A second compound, ADL5747, is targeted for an investigational new drug application (IND) by year end 2007. On the basis of preclinical evaluation in animal models of human conditions, one might expect a Delta agonist to show effect in inflammatory pain, among other pain conditions. In addition, Delta agonists are thought to modulate other biological processes that may manifest themselves in disease states or conditions such as overactive bladder and depression.
With no selective Delta agonists currently approved by the FDA, our Delta program is expanding the frontiers of pain research.
interestingly they are also working on a way to deliver this drug to inflammed parts of the body as there is proof that opioids applied directly to inflamed tissue like skin, eyes, and joints also reduces pain transmission. this is called peripheral opioid analgesia. they are trying to selectively stimulate opioid receptors in inflammed tissue and not in the CNS.